MediciNova, Inc. announced that it has received an issue notification from the U.S. Patent and Trademark Office for a new patent which covers extended-release oral formulations of MN-166 (ibudilast). This new patent is expected to commence no earlier than September 2040. The allowed claims cover a formulation in the form of a tablet or capsule and cover a range of doses of MN-166 (ibUDilast).
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.365 USD | +1.11% | 0.00% | -7.33% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.33% | 66.21M | |
+17.55% | 123B | |
+16.91% | 111B | |
-9.00% | 23.63B | |
+4.40% | 22.58B | |
-38.15% | 17.61B | |
-7.46% | 17.6B | |
-15.36% | 17.26B | |
+3.46% | 13.55B | |
+28.20% | 11.34B |
- Stock Market
- Equities
- MNOV Stock
- News MediciNova, Inc.
- MediciNova, Inc. Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166